AD-SysNCT05098821
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 2 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Dec 31, 2025 to Nov 8, 2024
- Secondary endpoints: details revised at 2 of 3 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Comparison of T-cell inflammatory markers
Timeframe: 1 year
Secondary (3)
Different T-cell pattern with dupilumab therapy
Assign recognition patterns to clinical symptoms
Connection of molecular profile and phenotype
Arms and interventions
Dupilumab treated Patients
Patients with atopic dermatitis with indication for dupilumab treatments will be observed
Other: not applicable, observational study
Sites
1 site in 1 country
- Dpt of Dermatology and Allergology, Charité - Universitätsmedizin BerlinBerlin, Germany